News

Smoking is associated with lower brain volume, more brain lesions, and greater disability and attention deficits among people with relapsing-remitting multiple sclerosis (RRMS) after 10 years, according to a study in Norway. “The findings imply that patients should be advised and offered aid in smoking cessation shortly after diagnosis, to…

Fully vaccinated multiple sclerosis (MS) patients who are treated with Ocrevus (ocrelizumab) or Gilenya (fingolimod) have a significantly higher risk of COVID-19 infection than those given other immunosuppressive therapies, according to a study in Italy. Called breakthrough infections, these post-vaccination cases of SARS-CoV-2 — the virus that causes…

Lower levels of income and education, as well as other socioeconomic factors, are associated with the presence and severity of fatigue among people with multiple sclerosis (MS), a new study in Norway found. Women, smokers, and those with other co-existing conditions or a higher disability level also were more…

An MRI technique called quantitative susceptibility mapping (QSM) can be used to accurately identify remyelinated brain lesions in people with multiple sclerosis (MS), a research team has discovered. Remyelinated lesions are those in which the myelin sheath — the protective coating around nerve fibers that is progressively lost…

Taking the pregnancy hormone estriol in combination with Copaxone (glatiramer acetate) significantly reduced the blood levels of neurofilament light chain (NfL) — a marker of nerve damage — in women with relapsing-remitting multiple sclerosis (RRMS), clinical trial data show. These lower NfL levels were significantly associated with a…

An assistive device made it significantly easier and more comfortable for multiple sclerosis (MS) patients with arm and hand mobility problems to self-administer nabiximols — an oral spray containing compounds found in the cannabis plant — a study found. Trained nurses involved in the study agreed with its…

The safety and efficacy of the approved multiple sclerosis (MS) therapy Mavenclad (cladribine) in a real-world group of patients were similar to what had been demonstrated in clinical trials, a new study reports. Among 243 people with relapsing-remitting multiple sclerosis (RRMS), more than 60% showed no…

The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on Phase 3 trials testing the investigational therapy tolebrutinib in people with multiple sclerosis (MS) and myasthenia gravis based on reports of medication-induced liver injury. Under the clinical hold, new enrollment at U.S. sites…

Fatigue is a common symptom among people living with multiple sclerosis (MS), and has a significant negative impact on physical and psychological function, as well as quality of life, a U.K. study reported. Citing the study as the “largest study on fatigue in MS from U.K.,”  researchers emphasized that…

Long-term treatment with Zeposia (ozanimod) stabilizes or even improves cognitive function in adults with relapsing forms of multiple sclerosis (MS), particularly among those with greater brain volumes. That’s according to five years of data from the completed SUNBEAM Phase 3 clinical trial (NCT02294058) and the ongoing…

The Phase 3 RELEASE MSS1 clinical trial testing nabiximols oral spray failed to meet its primary goal of easing leg spasticity in patients with multiple sclerosis (MS), according to Jazz Pharmaceuticals, the company currently developing the nabiximols clinical program. Enrolling 68 MS patients,…

OM1 has created an artificial intelligence (AI)-based algorithm to estimate scores on the expanded disability status scale (EDSS), an established method for evaluating disability and disease progression in people with multiple sclerosis (MS). The algorithm, using a method called machine learning, was trained to estimate EDSS scores…

Ublituximab, an investigational antibody-based treatment for multiple sclerosis (MS), was efficacious across most patient subgroups, and led to marked improvements in disability and quality of life over nearly two years. This is according to new exploratory analyses from the identical Phase 3 ULTIMATE I and II trials, which evaluated…

People with relapsing forms of multiple sclerosis (MS) who were continuously on Kesimpta (ofatumumab) for up to four years were about four times more likely to have no evidence of disease activity than those initially on Aubagio (teriflunomide), according to updated data from the ASCLEPIOS and ALITHIOS…

A short course of high-dose methylprednisolone was associated with signs of mild liver injury in nearly 3% of multiple sclerosis patients given this treatment, according to a study in Iran. Notably, a history of alcohol abuse and hyperlipidemia — higher-than-normal blood levels of fatty molecules such as cholesterol — were…

Proteins called tenascins block the regeneration of myelin by modulating the activity of oligodendrocytes, myelin-making cells of the central nervous system, a study in mouse models indicates. “Our research results open up new therapeutic approaches for the treatment of demyelinating diseases such as multiple sclerosis,” Juliane Bauch, a researcher at Ruhr-University…

Black Americans with multiple sclerosis (MS) have a higher chance of having uncontrolled high blood pressure (hypertension), despite being more likely to receive anti-hypertensive medication than white patients, a large study found. Further studies are needed to confirm these findings and…

The National Institute for Health and Care Excellence (NICE) in England has updated its guidelines for the diagnosis and management of adults with multiple sclerosis (MS). Called Multiple sclerosis in adults: management, the new guidelines update and replace the 2014 recommendations and are meant to be followed by…

Biogen has secured a new patent in Europe covering the use of its oral therapy Tecfidera (dimethyl fumarate) for multiple sclerosis (MS) through 2028, the company announced. Granted by the European Patent Office, patent EP2653873 covers the composition and use of dimethyl fumarate at a dose of 480…

Autologous hematopoietic stem cell transplant (aHSCT) has shown some promise as a treatment option for highly active relapsing-remitting multiple sclerosis (RRMS), but more clinical evidence is needed to support its use, a team of researchers in the U.K. suggest. “Uncertainty remains as to how aHSCT compares with current…

The risk of erectile dysfunction was about three times greater in men with multiple sclerosis (MS) compared with healthy men, according to a recent meta-analysis of published studies. It was identified in nearly half of the 2,760 adult male patients in these studies, highlighting the importance of diagnosing…

The Multiple Sclerosis Society of Canada has opened MS Bike, an annual cycling event to raise awareness and funds for research and services that make the difference for the more than 90,000 Canadians living with multiple sclerosis (MS). Conducted in an entirely virtual format due to COVID-19 in 2020…

Alcohol intake is not significantly associated with an increased risk of developing multiple sclerosis (MS), but specifically drinking beer may elevate the risk, according to a recent meta-analysis. The association, however, was limited by a small number of included studies. “Further large-scale prospective studies should be conducted to verify…

Unusual growth in an immune cell class called myeloid cells is evident in the bone marrow of people with multiple sclerosis (MS), and these cells likely contribute to the inflammation that drives the disease, according to a new study. Experiments in mice suggest that myelin-reactive T-cells can migrate to the bone…

Cionic‘s leg-worn Neural Sleeve, recently authorized in the U.S. to aid walking in people with multiple sclerosis (MS) and other conditions that impair mobility, reduced foot drop in a small clinical trial. Patients in the trial also reported marked reductions in pain and mental health problems, according to…

Cresence AS has sold its epidermal growth factor (EGF) platform comprising investigational therapies for multiple sclerosis (MS) and other neurodegenerative diseases to Bioasis Technologies. Under the terms of the agreement, Bioasis will own all intellectual property related to the EGF platform. In exchange, it will issue…

Treatment with the experimental immune-modulating therapy vidofludimus calcium reduced disease activity on MRI scans in adults with relapsing-remitting multiple sclerosis (RRMS), data from the Phase 2 EMPhASIS clinical trial shows. Top-line results from EMPhASIS were reported by the therapy’s developer Immunic Therapeutics in 2020. Researchers at…

Innovative Trials has selected the MS Society UK as its charity partner for the next year, and intends to raise at least £3,000 (about $3,600) to support multiple sclerosis (MS) research and the society’s quest for a world without MS. Innovative Trials works with pharmaceutical companies and…

A new tool called signal detection theory (SDT) found a relationship between subjective cognitive fatigue, often experienced by people with multiple sclerosis (MS), and the activation of certain brain regions, a study reported. Although the relationship was found in both patients and healthy controls after cognitive fatigue was…

Treatment with foralumab nasal spray resulted in marked clinical improvements after three months in the second secondary progressive multiple sclerosis (SPMS) patient treated under a single-patient access program. The findings were generally consistent with those seen in the first SPMS patient and supported a decision by the U.S. Food…